OncoMatch/Clinical Trials/NCT04762199
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Is NCT04762199 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Flt3/MerTK Inhibitor MRX-2843 and Osimertinib for advanced lung non-small cell carcinoma.
Treatment: Flt3/MerTK Inhibitor MRX-2843 · Osimertinib — This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR
activating EGFR mutation including typical and atypical mutations in egfr exons 19 and 21
Required: EGFR T790M
If not previously treated with osimertinib, must be EGFR-T790M negative as confirmed using a standard testing platform (circulating tumor deoxyribonucleic acid [ctDNA] or tissue based testing) prior to study treatment
Disease stage
Required: Stage IV, IVA, IVB
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Cannot have received: radiation therapy
Exception: within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Cannot have received: investigational agent
Patients who are receiving any other investigational agents
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1500/mm^3; Platelet count ≥ 100,000/mm^3; Hemoglobin ≥ 8.5 g/dL (must be > 2 weeks post-red blood cell transfusion)
Kidney function
Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 50 mL/min (Cockcroft and Gault equation)
Liver function
Bilirubin ≤ 1.5 x ULN (≤ 3.0 mg/dL for Gilbert's disease, ≤ 2.5 x ULN for liver metastases); ALT and AST ≤ 3 x ULN (≤ 5 x ULN for liver metastases)
Cardiac function
QTc interval ≤ 500 msec (average of 3 readings); no known cardiomyopathy or LVEF < 50%
Absolute neutrophil count ≥ 1500/mm^3; Platelet count ≥ 100,000/mm^3; Hemoglobin ≥ 8.5 g/dL (must be > 2 weeks post-red blood cell transfusion); Bilirubin ≤ 1.5 x ULN (≤ 3.0 mg/dL for Gilbert's disease, ≤ 2.5 x ULN for liver metastases); Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 50 mL/min; ALT and AST ≤ 3 x ULN (≤ 5 x ULN for liver metastases); QTc interval ≤ 500 msec (average of 3 readings); no known cardiomyopathy or LVEF < 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify